{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:31:50Z","timestamp":1790706710351,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2014,12,19]],"date-time":"2014-12-19T00:00:00Z","timestamp":1418947200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1007\/s12185-014-1721-9","type":"journal-article","created":{"date-parts":[[2014,12,19]],"date-time":"2014-12-19T06:52:43Z","timestamp":1418971963000},"page":"148-153","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Consequences of the JAK2V617F allele burden for the prediction of transformation into myelofibrosis from polycythemia vera and essential thrombocythemia"],"prefix":"10.1007","volume":"101","author":[{"given":"Shuichi","family":"Shirane","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marito","family":"Araki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soji","family":"Morishita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Edahiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Sunami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumi","family":"Hironaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Noguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiaki","family":"Koike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eriko","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akimichi","family":"Ohsaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Komatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,12,19]]},"reference":[{"key":"1721_CR1","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.leukres.2010.07.019","volume":"35","author":"RA Mesa","year":"2011","unstructured":"Mesa RA, et al. MPN-associated myelofibrosis (MPN-MF). Leuk Res. 2011;35:12\u20133.","journal-title":"Leuk Res."},{"key":"1721_CR2","doi-asserted-by":"crossref","first-page":"5587","DOI":"10.1200\/JCO.2009.22.8833","volume":"27","author":"CS Tam","year":"2009","unstructured":"Tam CS, et al. Dynamic model for predicting death within 12\u00a0months in patients with primary or post-polycythemia vera\/essential thrombocythemia myelofibrosis. J Clin Oncol. 2009;27:5587\u201393.","journal-title":"J Clin Oncol."},{"key":"1721_CR3","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1182\/blood-2007-11-121434","volume":"111","author":"F Passamonti","year":"2008","unstructured":"Passamonti F, et al. A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis. Blood. 2008;111:3383\u20137.","journal-title":"Blood."},{"key":"1721_CR4","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","volume":"7","author":"RL Levine","year":"2005","unstructured":"Levine RL, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387\u201397.","journal-title":"Cancer Cell."},{"key":"1721_CR5","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","volume":"365","author":"EJ Baxter","year":"2005","unstructured":"Baxter EJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054\u201361.","journal-title":"Lancet."},{"key":"1721_CR6","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","volume":"352","author":"R Kralovics","year":"2005","unstructured":"Kralovics R, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779\u201390.","journal-title":"N Engl J Med."},{"key":"1721_CR7","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","volume":"434","author":"C James","year":"2005","unstructured":"James C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434:1144\u20138.","journal-title":"Nature."},{"key":"1721_CR8","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/j.1365-2141.2009.07804.x","volume":"146","author":"A Alvarez-Larran","year":"2009","unstructured":"Alvarez-Larran A, et al. Postpolycythaemic myelofibrosis: frequency and risk factors for this complication in 116 patients. Br J Haematol. 2009;146:504\u20139.","journal-title":"Br J Haematol."},{"key":"1721_CR9","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.leukres.2010.06.017","volume":"35","author":"RT Silver","year":"2011","unstructured":"Silver RT, et al. JAK2(V617F) allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapy. Leuk Res. 2011;35:177\u201382.","journal-title":"Leuk Res."},{"key":"1721_CR10","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/leu.2010.148","volume":"24","author":"F Passamonti","year":"2010","unstructured":"Passamonti F, et al. A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia. 2010;24:1574\u20139.","journal-title":"Leukemia."},{"key":"1721_CR11","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/cncr.21645","volume":"106","author":"A Tefferi","year":"2006","unstructured":"Tefferi A, et al. The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera. Cancer. 2006;106:631\u20135.","journal-title":"Cancer."},{"key":"1721_CR12","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood-2006-12-064287","volume":"110","author":"AM Vannucchi","year":"2007","unstructured":"Vannucchi AM, et al. Clinical profile of homozygous JAK2 617\u00a0V\u00a0>\u00a0F mutation in patients with polycythemia vera or essential thrombocythemia. Blood. 2007;110:840\u20136.","journal-title":"Blood."},{"key":"1721_CR13","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/ajh.23676","volume":"89","author":"A Alvarez-Larran","year":"2014","unstructured":"Alvarez-Larran A, et al. JAK2V617F monitoring in polycythemia vera and essential thrombocythemia: clinical usefulness for predicting myelofibrotic transformation and thrombotic events. Am J Hematol. 2014;89:517\u201323.","journal-title":"Am J Hematol."},{"issue":"1186\u20131193","key":"1721_CR14","first-page":"e7","volume":"37","author":"K Hussein","year":"2009","unstructured":"Hussein K, et al. JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis. Exp Hematol. 2009;37(1186\u20131193):e7.","journal-title":"Exp Hematol."},{"key":"1721_CR15","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1016\/j.leukres.2011.06.016","volume":"3512","author":"S Morishita","year":"2011","unstructured":"Morishita S, et al. Alternately binding probe competitive PCR as a simple, cost-effective, and accurate quantification method for JAK2V617F allele burden in myeloproliferative neoplasms. Leuk Res. 2011;3512:1632\u20136.","journal-title":"Leuk Res."},{"key":"1721_CR16","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/sj.leu.2404914","volume":"22","author":"G Barosi","year":"2008","unstructured":"Barosi G, et al. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia. 2008;22:437\u20138.","journal-title":"Leukemia."},{"key":"1721_CR17","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s00277-008-0512-x","volume":"87","author":"I Rapado","year":"2008","unstructured":"Rapado I, et al. Validity test study of JAK2 V617F and allele burden quantification in the diagnosis of myeloproliferative diseases. Ann Hematol. 2008;87:741\u20139.","journal-title":"Ann Hematol."},{"key":"1721_CR18","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1182\/blood-2013-07-515676","volume":"122","author":"K Takahashi","year":"2013","unstructured":"Takahashi K, et al. JAK2 p. V617F detection and allele burden measurement in peripheral blood and bone marrow aspirates in patients with myeloproliferative neoplasms. Blood. 2013;122:3784\u20136.","journal-title":"Blood."},{"key":"1721_CR19","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/sj.leu.2404861","volume":"22","author":"TS Larsen","year":"2008","unstructured":"Larsen TS, et al. Quantitative assessment of the JAK2 V617F allele burden: equivalent levels in peripheral blood and bone marrow. Leukemia. 2008;22:194\u20135.","journal-title":"Leukemia."},{"key":"1721_CR20","doi-asserted-by":"crossref","first-page":"722","DOI":"10.3324\/haematol.2012.076901","volume":"98","author":"T Lange","year":"2013","unstructured":"Lange T, et al. JAK2 p. V617F allele burden in myeloproliferative neoplasms 1\u00a0month after allogeneic stem cell transplantation significantly predicts outcome and risk of relapse. Haematologica. 2013;98:722\u20138.","journal-title":"Haematologica."},{"key":"1721_CR21","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.3324\/haematol.13346","volume":"93","author":"F Passamonti","year":"2008","unstructured":"Passamonti F, et al. Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients. Haematologica. 2008;93:1645\u201351.","journal-title":"Haematologica."},{"key":"1721_CR22","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1038\/sj.leu.2404693","volume":"21","author":"A Alvarez-Larran","year":"2007","unstructured":"Alvarez-Larran A, et al. Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients. Leukemia. 2007;21:1218\u201323.","journal-title":"Leukemia."},{"key":"1721_CR23","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1200\/JCO.2010.34.5298","volume":"29","author":"T Barbui","year":"2011","unstructured":"Barbui T, et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol. 2011;29:3179\u201384.","journal-title":"J Clin Oncol."},{"key":"1721_CR24","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.3109\/10428194.2012.682308","volume":"53","author":"M Koren-Michowitz","year":"2012","unstructured":"Koren-Michowitz M, et al. JAK2V617F allele burden is associated with transformation to myelofibrosis. Leuk Lymphoma. 2012;53:2210\u20133.","journal-title":"Leuk Lymphoma."},{"key":"1721_CR25","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s12185-014-1567-1","volume":"99","author":"Y Edahiro","year":"2014","unstructured":"Edahiro Y, et al. JAK2V617F mutation status and allele burden in classical Ph-negative myeloproliferative neoplasms in Japan. Int J Hematol. 2014;99:625\u201334.","journal-title":"Int J Hematol."},{"key":"1721_CR26","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1200\/JCO.2005.07.062","volume":"23","author":"R Marchioli","year":"2005","unstructured":"Marchioli R, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol. 2005;23:2224\u201332.","journal-title":"J Clin Oncol."},{"key":"1721_CR27","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.3324\/haematol.12801","volume":"93","author":"A Ricksten","year":"2008","unstructured":"Ricksten A, et al. Rapid decline of JAK2V617F levels during hydroxyurea treatment in patients with polycythemia vera and essential thrombocythemia. Haematologica. 2008;93:1260\u20131.","journal-title":"Haematologica."},{"key":"1721_CR28","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.3324\/haematol.13074","volume":"93","author":"A Theocharides","year":"2008","unstructured":"Theocharides A, et al. The allele burden of JAK2 mutations remains stable over several years in patients with myeloproliferative disorders. Haematologica. 2008;93:1890\u20133.","journal-title":"Haematologica."},{"key":"1721_CR29","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.3324\/haematol.13081","volume":"93","author":"F Girodon","year":"2008","unstructured":"Girodon F, et al. Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy. Haematologica. 2008;93:1723\u20137.","journal-title":"Haematologica."},{"key":"1721_CR30","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1365-2141.2010.08467.x","volume":"152","author":"C Besses","year":"2011","unstructured":"Besses C, et al. Modulation of JAK2 V617F allele burden dynamics by hydroxycarbamide in polycythaemia vera and essential thrombocythaemia patients. Br J Haematol. 2011;152:413\u20139.","journal-title":"Br J Haematol."},{"key":"1721_CR31","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1179\/102453309X385188","volume":"14","author":"TS Larsen","year":"2009","unstructured":"Larsen TS, et al. Limited efficacy of hydroxyurea in lowering of the JAK2 V617F allele burden. Hematology. 2009;14:11\u20135.","journal-title":"Hematology."},{"key":"1721_CR32","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.3324\/haematol.2009.021444","volume":"95","author":"E Antonioli","year":"2010","unstructured":"Antonioli E, et al. Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia. Haematologica. 2010;95:1435\u20138.","journal-title":"Haematologica."},{"key":"1721_CR33","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.3324\/haematol.2010.037846","volume":"96","author":"IR Zalcberg","year":"2011","unstructured":"Zalcberg IR, et al. Hydroxyurea dose impacts hematologic parameters in polycythemia vera and essential thrombocythemia but does not appreciably affect JAK2-V617F allele burden. Haematologica. 2011;96:e18\u201320.","journal-title":"Haematologica."}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-014-1721-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-014-1721-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-014-1721-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T05:11:22Z","timestamp":1559452282000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-014-1721-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,19]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["1721"],"URL":"https:\/\/doi.org\/10.1007\/s12185-014-1721-9","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,19]]}}}